A clinical study of TG6002 and flucytosine in patients with gastro-intestinal tumors

ABSTRACT: Primary objectives: Phase I: determination of the recommended phase II dose Phase IIa: efficacy of multiple administrations of TG6002 in combination with flucytosine (or Ancotil or 5-FC) Primary endpoints: Phase I: adverse events, serious adverse events, change in standard laboratory parameters and vital signs, dose-limiting toxicities. Phase IIa: overall response rate.

DISEASE(S): Gastro-intestinal Cancer,Gastrointestinal Cancer Metastatic,Cancer Gastro-intestinal

PROVIDER: 2537744 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR